Core Insights - INmune Bio Inc. is hosting a webinar on February 26, 2026, to discuss CORDStrom for treating recessive dystrophic epidermolysis bullosa (RDEB) and present new data from the MissionEB clinical study [1][2] Group 1: CORDStrom Overview - CORDStrom™ is a patent-pending cell medicine made from aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) designed for injection or infusion [4] - The platform utilizes proprietary techniques for screening, pooling, and expanding hucMSCs, allowing for the creation of off-the-shelf medicines for complex inflammatory and autoimmune diseases [4] - CORDStrom™ products aim to provide consistent, scalable, and affordable cellular medicines with optimized characteristics for various indications [4] Group 2: Clinical Trial Insights - The upcoming webinar will highlight the systemic disease-modifying capabilities of CORDStrom™ in RDEB patients, contrasting it with current standard-of-care options that focus on topical treatments [2] - Key clinical benchmarks to be discussed include improvements in the EBDASI (EB Disease Activity and Scarring Index), nutritional and weight gain data in pediatric patients, reductions in pain and itch, and enhancements in quality of life [6] - Principal investigators, including Dr. Anna Martinez and Prof. Mark Lowdell, will provide insights from the MissionEB study, emphasizing the systemic nature of RDEB and the scientific rationale for using CORDStrom™ [6][3] Group 3: Company Background - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms: CORDStrom™, XPro™, and INKmune® [7] - The company is publicly traded on NASDAQ under the ticker INMB and is dedicated to advancing therapies for various diseases [7]

Core Points - INmune Bio Inc. will host a conference call on October 30, 2025, at 4:30 PM ET to discuss its third-quarter results and provide a corporate update [1][2] - The company is a clinical-stage biotechnology firm focused on developing treatments targeting the innate immune system [3] Company Overview - INmune Bio Inc. is publicly traded on NASDAQ under the ticker INMB [3] - The company has three product platforms: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which neutralizes soluble TNF to address immune dysfunction [3] - CORDStrom™, a proprietary platform using human umbilical cord-derived mesenchymal stromal/stem cells, which recently completed a trial for recessive dystrophic epidermolysis bullosa [3] - INKmune®, designed to enhance natural killer cells to target minimal residual disease in cancer patients, currently in trials for metastatic castration-resistant prostate cancer [3]

Core Insights - INmune Bio, Inc. is participating in the Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025, where CEO David Moss will discuss the company's CORDStrom™ platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1][2] Company Overview - INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [3] - The company has three product platforms: - Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which neutralizes soluble TNF to address immune dysfunction [3] - CORDStrom™, a proprietary platform using human umbilical cord-derived mesenchymal Stromal/Stem cells, which has completed a blinded randomized trial for RDEB [3] - INKmune®, designed to enhance natural killer cells to eliminate minimal residual disease in cancer patients, currently in trials for metastatic castration-resistant prostate cancer [3] Event Details - The Maxim Growth Summit will be held at the Hard Rock Hotel in New York City, with David Moss available for one-on-one meetings throughout the conference [1][2]